Pharsight

Drugs that contain Vorinostat

1. Zolinza patents expiration

ZOLINZA's oppositions filed in EPO
Can you believe ZOLINZA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7456219 MERCK Polymorphs of suberoylanilide hydroxamic acid
Mar, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7652069 MERCK Polymorphs of suberoylanilide hydroxamic acid
Mar, 2023

(11 months ago)

US8101663 MERCK Polymorphs of suberoylanilide hydroxamic acid
Mar, 2023

(11 months ago)

US7732490 MERCK Methods of treating cancer
Mar, 2023

(11 months ago)

US8067472 MERCK Methods of treating Hodgkin's and non-Hodgkin's lymphoma
Mar, 2023

(11 months ago)

US7851509 MERCK Polymorphs of suberoylanilide hydroxamic acid
Feb, 2024

(9 days ago)

US7399787 MERCK Methods of treating cancer with HDAC inhibitors
Feb, 2025

(11 months from now)

US8093295 MERCK Formulations of suberoylanilide hydroxamic acid and methods for producing the same
May, 2026

(2 years from now)

US8450372 MERCK Formulations of suberoylanilide hydroxamic acid and methods for producing same
Mar, 2028

(4 years from now)

Market Authorisation Date: 06 October, 2006

Treatment: Treatment of cutaneous manifestations in patients wtih cutaneous t-cell lymphoma (ctcl)

Dosage: CAPSULE;ORAL

More Information on Dosage

ZOLINZA family patents

Family Patents